EUROPEAN COMMISSION
HEALTH & CONSUMERS DIRECTORATE-GENERAL

Directorate D - Health systems and products
D3 – Pharmaceuticals
Head of unit

Brussels, 10 August 2011

NOTE TO THE MEMBERS OF THE STANDING COMMITTEE ON MEDICINAL PRODUCTS FOR HUMAN USE/STANDING COMMITTEE ON VETERINARY MEDICINAL PRODUCTS

Subject: **Adoption of COMMISSION IMPLEMENTING DECISION withdrawing, at the holder´s request, the marketing authorisation for "Yarvitan - Mitratapide", a medicinal product for veterinary use, granted by Decision C(2006)5549**

EU/2/06/063/001-003 – EMEA/V/C/113/withdrawal

The Commission has adopted the abovementioned Decision on 10 August 2011.

The Decision will be notified forthwith to the addressee(s) of the Decision.[1]

The Decision is going to be published for information in all official languages of the EU in the Community Register of Medicinal Products (http://ec.europa.eu/health/documents/community-register/index_en.htm) after the Decision has been notified. The attention has to be drawn to the fact that, under the general rules of the EC Treaty, a Decision is a legal act whose publication is not obligatory in order to be binding.

Patricia Brunko
pp. Jones Sharon

Cc: Marketing authorisation holder (Contact person, only in centralised procedure);

EMA (Product team leader, secretary)

[1] In case of centralised procedure: Marketing Authorization Holder; In case of referral procedure: Member States (via the Permanent Representations to the European Union)

Commission européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel - Belgium. Telephone: (32-2) 299 11 11.
Office: BREY 10/106. Telephone: direct line (32-2) 2962587. Fax: (32-2) 2998046.
E-mail: Patricia.Brunko@ec.europa.eu